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Background: Lymphangiogenesis plays a significant role in metastasis and recurrence of gastric cancer. There is
no report yet focusing on the modulation of VEGF pathway and lymphangiogenesis of gastric cancer by targeting
Akt/mTOR pathway. This study aims to demonstrate the relationship between Akt/mTOR pathway and VEGF-C/-D in
gastric cancer.
Methods: We collected surgically resected gastric adenocarcinoma specimens from 55 consented patients.
Immunohistochemistry staining of p-Akt, p-mTOR, VEGF-C, VEGF-D were performed and scored by two independent
pathologists. The results were presented as staining intensity and positive staining cell rate. We also measured
lymphatic vessel density (LVD) by D2-40 staining. Different dosages of p-Akt inhibitor LY294002 (12.5 μM, 25 μM,
50 μM) and p-mTOR inhibitor Rapamycin (25 nM, 50 nM, 100 nM) were given to gastric cancer cell line SGC-7901
in vitro. The inhibition rate of cell growth was tested by MTT at 24 h, 48 h and 72 h, respectively and protein
expressions of Akt, p-Akt, mTOR, p-mTOR, VEGF-C and VEGF-D were examined by Western blot.
Results: The positive staining rates of p-Akt, p-mTOR, VEGF-C and VEGF-D in 55 gastric cancer clinical specimens
were 74.54%, 85.45%, 72.73% and 58.18%. p-Akt and p-mTOR were positively correlated with VEGF-C and VEGF-D
(p < 0.01). The LVD increased with incremental tendency of staining intensity of p-Akt, p-mTOR, VEGF-C and VEGF-D.
LY294002 or Rapamycin significantly suppressed SGC-7901 cell growth and the inhibition rate was dose and time
dependent (p < 0.001). In addition, the protein expression of p-Akt and p-mTOR were positively correlated with that
of VEGF-C and VEGF-D (p < 0.05).
Conclusions: The level of LVD in gastric cancer specimens was significant higher than that of normal gastric tissue
and was positively correlated with p-Akt, p-mTOR, VEGF-C and VEGF-D. Inhibition of p-Akt and p-mTOR, in vitro,
decreased tumor cell VEGF-C and VEGF-D significantly. Therefore, we concluded that lymphangiogenesis of gastric
cancer might be related to Akt/mTOR-VEGF-C/VEGF-D axis.
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Gastric cancer is one of the most common malignant
neoplasms worldwide [1-3]. Common treatment strat-
egies for gastric cancer include surgery, radiotherapy,
chemotherapy and targeted therapy [4,5]. Treatment fail-
ures include metastasis and recurrence after operation.
The main metastatic routes of gastric cancer are direct
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unless otherwise stated.enterocoelia metastasis [3]. Among those, lymphatic me-
tastasis is an increasingly important criterion in judging
the prognosis of gastric carcinoma and lymphangiogen-
esis is recognized as a significant predictor for the prog-
nosis of patients with gastric cancer [1,2]. In addition,
the stomach cancer lymphatic metastasis is believed to
be an earlier event compared to vascular metastasis,
happening even in early stage gastric cancer [3,4]. There-
fore, the International Union against Cancer took the
lymphangiogenesis rate and the metastasis amount of the
lymph node into the staging of gastric cancer in evaluating
the prognosis [2,5]. Besides, even if lymphadenectomy andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lymph node negative progression, it also brought the posi-
tive effect on improving the 5-year survival rate of gastric
cancer [5].
The two established ways of tumor cells entry into the
lymprhatic system are invasion of existing lymphatic
ducts and induction of lymphangiogenesis [3]. The latter
is considered as the major way. In addition, lymphangio-
genesis plays a decisive role in metastasis, recurrence
and prognosis in early gastric cancer [4]. Thus, studies
of lymphangiogenesis have a promising impact on the
treatment. VEGF-C and VEGF-D were positively related
to solid tumor lymphatic metastasis, lymphatic vessel
density (LVD) and depth of tumor invasion and recur-
rence according to previous studies [6-8]. Besides, Akt/
mTOR pathway is also involved in the regulation of
lymphangiogenesis and lymphatic metastasis [9-11].
Therefore, the relationship between Akt/mTOR path-
way and VEGF pathways is worthy to be elucidated.
To our knowledge, there is no report yet focusing on
the modulation of VEGF pathway and lymphangiogenesis
by targeting Akt/mTOR pathway in gastric cancer. In this
study, we aim to demonstrate the relationship between
Akt/mTOR pathway and VEGF-C/-D in gastric cancer.
Methods
Clinical specimen
Surgical resected gastric adenocarcinoma specimens were
collected from 55 patients with gastric cancer from April
2011 to November 2012. All of them received no radio-
therapy, chemotherapy or immunotherapy before the op-
eration. The study was approved by ethics committee of
the First Affiliated Hospital of Nanchang University and
all participants gave written informed consent.
Immunohistochemistry
All tissue samples were fixed with 10% formalin, routinely
embedded in paraffin, cut into 4-μm thick as serial sec-
tions, dewaxed with xylene, rehydration with an ethanol
gradient and washed with distilled water. Antigen retrieval
was performed by submerging sections in antigenic re-
trieval buffer (0.5 M EDTA), and microwaving for 20 min.
Sections were then treated with 3% hydrogen peroxide
solution. The samples were blocked with 5% normal goat
serum and then incubated overnight at 4°C with the pri-
mary antibody: p-Akt (ser473) (Rabbit, 1:100, Cell Signal-
ing Technology, USA), p-mTOR (ser2448) (Rabbit, 1:200,
Abcam, USA), VEGF-C (Goat, 1:400, R&D, USA), VEGF-D
(Mouse, 1:50, Santa Cruz, USA) and D2-40 (Mouse, 1:100,
ZSGB-BIO, China). Then, second antibody was added, and
the samples were incubated for 30 min at room tem-
perature and then developed with DAB. 5% normal goat
serum was used as a negative control instead of the pri-
mary antibody. Immunohistochemistry staining was scoredby two independent pathologists. Results were presented in
the form of staining intensity (+/++/+++) and positive
staining cell rate.
Lymphatic vessel density
According to Masakau criteria, D2-40 positive staining
(single endothelial cell or cell clusters) was marked as
positive microlymphatic vessel. The vascular-rich area in
para-neoplastic location and tumor center were defined
and 5 fields of “hot spots” were randomly counted under
high magnification (×400). The average was counted as
the LVD.
Cell survival
Three different dosages (12.5 μM, 25 μM, 50 μM) of Akt
activation inhibitor LY294002 (Sigma) or mTOR acti-
vation inhibitor (25 nM, 50 nM, 100 nM) Rapamycin
(Sigma) were given to gastric cancer cell line SGC-7901.
The inhibition rate of cell growth was tested by MTT
assay at 24 h, 48 h and 72 h, respectively.
Western blot
SGC-7901 cells were homogenized in RIPA lysis buffer
(10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 600 mM NP-40,
1% Triton X-100, 10% glycerol, 1 mM phenylmethylsulfonyl
fluoride, 1 mM sodium fluoride, and 1 mM sodium ortho-
vanadate) and put on ice for 2 h. Protein concentration of
each sample was determined by Bio-Rad Protein Assay kit
(Bio-Rad, Laboratories, Hercules, CA, USA) according to
the instruction of manufacturer. Lysates containing 50 μg
of protein were separated by SDS-PAGE and then trans-
ferred to nitrocellulose membranes. Nonspecific reac-
tions were blocked for 4 h with TBS-T (50 mM Tris.
HCl, pH7.4, 150 mM NaCl, 0.1% Tween 20) containing
5% non-fat dry milk. Then membranes were incubated
overnight at 4°C with primary antibody: Akt (Mouse,
1:2000, Cell Signaling Technology, USA), p-Akt (ser473)
(Rabbit, 1:2000, Cell Signaling Technology, USA), mTOR
(Rabbit, 1:1000, Cell Signaling Technology, USA), p-mTOR
(ser2448) (Rabbit, 1:3000, Abcam, USA), VEGF-C (Goat,
1:1000, R&D, USA) and VEGF-D (Mouse, 1:500, Santa
Cruz, USA). After being washed with TBS-T containing
non-fat dry milk, the membranes were incubated with
horseradish peroxidase-conjugated secondary antibodies.
The protein blots were visualized by chemiluminescence
using ECL (Amersham).
Statistical analysis
Independent samples T test between two groups and
single factor analysis of variance (ANOVA) for multiple
comparisons were utilized when the data in accordance
with normal distribution and homogeneity of variance.
Otherwise, Mann–Whitney test between two groups and
Kruskal-Wallis test among multi-groups were conducted.
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measurement and count data. Statistical analyses were
performed by SPSS17.0 (SPSS Inc., Chicago, IL, USA). A
p-value of < 0.05 was considered statistically significant.
Results
Expression of p-Akt, p-mTOR, VEGF-C and VEGF-D in situ
The immunohistochemistry stainings of p-Akt, p-mTOR,
VEGF-C and VEGF-D in 55 gastric cancer clinical speci-
mens were shown (Figure 1). The positive staining pre-
sented mostly in cytoplasm and a few nuclear stained
in p-Akt and p-mTOR. The positivity rates of p-Akt,
p-mTOR, VEGF-C and VEGF-D were 74.54%, 85.45%,
72.73% and 58.18% respectively. The quantification of
staining intensity was shown in Table 1.
The correlations of p-Akt and p-mTOR/VEGF-C/
VEGF-D, p-mTOR and VEGF-C/VEGF-D were furtherFigure 1 Immunohistochemistry staining of p-Akt, p-mTOR, VEGF-C a
C: VEGF-C, D: VEGF-D, E: The correlation between p-Akt and p-mTOR/VEGFanalyzed. p-Akt expression was positively correlated with
p-mTOR (p = 0.001), VEGF-C (p = 0.002) and VEGF-D
(p = 0.009) (Figure 1E). Besides, p-mTOR was also sig-
nificantly positive related to VEGF-C (p < 0.001) and
VEGF-D (p = 0.003).
Lymphatic vessel density
D2-40 staining was used to calculate the LVD for gastric
cancer (Figure 2A) and matched normal gastric tissue
(Figure 2B). According to the results, D2-40 stained
mainly in lymphatic endothelium in scattered or clustered
distribution. Thin lymphatic vessel wall was lacking basal
layer. The highest LVD was observed at the edge of tumor
with a dense cluster-like morphology. In addition, D2-40
was expressed in the submucosa of normal tissue, with a
weaker expression in the mucosa or muscle layer as well.
The average LVD of gastric carcinoma and normal tissuend VEGF-D in gastric cancer specimen (×400). A: p-Akt, B: p-mTOR,
-C/VEGF-D.
Table 1 Immunohistochemistry staining of p-Akt, p-mTOR,
VEGF-C and VEGF-D in gastric cancer specimens
Intensity (n) Positive
rate (%)- + ++
p-Akt 14 29 12 74.54
p-mTOR 8 21 26 85.45
VEGF-C 15 22 18 72.73
VEGF-D 23 27 5 58.18
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power fields, p < 0.001.
LVD were positively correlated with p-Akt, p-mTOR,
VEGF-C and VEGF-D expression per Spearman analysis
(p < 0.05). LVD increased with the incremental tendency
of staining intensity of p-Akt, p-mTOR, VEGF-C and
VEGF-D (Figure 2C).
Effects of LY294002 and Rapamycin on SGC-7901 cell
growth
SGC-7901 cells were cultured with three different dosages
of LY294002 for 24 h, 48 h and 72 h. According to MTT
assay, SGC-7901 cell growth was curbed and the inhib-
ition rate was significantly correlated with LY294002 dos-
age and action time (p < 0.001) (Figure 3A).
Besides, cells were also cultured with different dosages
of Rapamycin for 24 h, 48 h and 72 h, respectively. The
inhibition rate of SGC-7901 was also significantly cor-
related with either Rapamycin dosage or action time
(p < 0.001) (Figure 3B). Therefore, both LY294002 andFigure 2 Immunohistochemistry staining of D2-40 for LVD
(×400). A: Gastric cancer tissue, B: Matched normal tissue, C: The
correlation between LVD and p-Akt/p-mTOR/VEGF-C/VEGF-D.
LVD = lymphatic vessel density.Rapamycin could inhibit the growth of SGC-7901 in
either time-dependent or dose-dependent manner.
Effect of LY294002 on Akt/mTOR pathway and VEGF-C/-D
The protein level of Akt, p-Akt, mTOR, p-mTOR,
VEGF-C and VEGF-D in SGC-7901 with LY294002
(50 μM) inhibition were examined by Western blot.
Among them, p-Akt, p-mTOR, VEGF-C and VEGF-D
were gradually decreased with the prolongation action
time of LY294002 (Figure 3C). There was a significant
difference when compared with the group without
LY294002 (p < 0.05). However, there was no statistical
difference for Akt and mTOR (p > 0.05). By further
conducting a dual variant relation analysis, p-Akt was
positively correlated with p-mTOR/VEGF-C/VEGF-D
(p < 0.05) and p-mTOR was also positively related to
VEGF-C/VEGF-D (p < 0.05).
Effect of Rapamycin on mTOR pathway and VEGF-C/-D
The protein level of Akt, p-Akt, mTOR, p-mTOR, VEGF-C
and VEGF-D in SGC-7901 with Rapamycin (100 nM) in-
hibition were examined by Western blot. Among them,
p-mTOR, VEGF-C and VEGF-D expression were de-
creased with the prolongation action time of Rapamycin
(Figure 3C). There was a significant difference when
compared with the group without Rapamycin (p < 0.05).
However, there was no statistical difference for Akt, p-
Akt and mTOR (p > 0.05). By further conducting a dual
variant relation analysis, p-mTOR was positively corre-
lated with VEGF-C and VEGF-D (p < 0.05).
Discussion
Akt/mTOR signaling pathway is an important intracellu-
lar pathway, which responds to cytokine signals, and is
proved to play a major role in cell growth, metabolism
and apoptosis [12,13]. Akt/mTOR pathway involves in
various pathological mechanisms of colorectal cancer,
gastric cancer, liver cancer, breast cancer and uterine
cancer etc. [12-14]. Our previous study confirmed that
p-Akt involved in angiogenesis of gastric adenocarcin-
oma and Akt activation may contribute to angiogenesis
via VEGF-A up-regulation [15]. In this study, the posi-
tive staining rates of p-Akt and p-mTOR in 55 cases of
gastric cancer were 74.54% and 85.45% respectively.
Besides, p-Akt was positively correlated with p-mTOR
(p < 0.01). This result was consistent with previous stud-
ies and confirmed the significant role of Akt/mTOR
pathway in gastric cancer. The clinical prognosis of
gastric cancer is also proposed to be associated with Akt
pathway and VEGF pathway. For instance, Murakami
et al. suggested that the prognosis of gastric cancer
patients without p-Akt expression was always better
than p-Akt positive ones, and the 5-year survival rates
were 68% and 35% for patients with T3 or T4 stage
Figure 3 Inhibition of p-Akt and p-mTOR in SGC-7901 cells by LY294002 and Rapamycin. A: SGC-7901 cell growth with intervention of
different time points and dosages of LY294002, B: SGC-7901 cell growth with intervention of different time points and dosages of Rapamycin,
C: Effect of LY294002 (50 μM) and Rapamycin (100 nM) on Akt/mTOR pathway and VEGF-C/-D by Western blot.
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PI3CA of upstream protein PI3K was associated with
disease-free survival [17]. In addition, Wang et al. indi-
cated that VEGF-C, VEGF-D and LVD of gastric cancer
were related to tumor size and overall survival according
to a study in 123 cases [18,19]. The correlation between
VEGF-C/LVD and prognosis in tumor differentiation, T
stage, lymph node metastasis, and distant metastasis
were also confirmed [20]. Another study further suggested
using the combination of VEGF-C/-D and CA199 to pre-
dict lymphatic vessel metastasis [21].
Given that Akt/mTOR pathway and VEGF-C/-D play
a vital role in lymphatic metastasis and prognosis, our
study aims to explore the relationship between two path-
ways and further promote the mechanism of lymphan-
giogenesis and metastasis. According to the results of
staining in situ, p-Akt and p-mTOR were positively cor-
related with VEGF-C and VEGF-D (p < 0.01). In terms of
LVD, D2-40 level of gastric carcinoma and normal tissues
were examined at the same time. LVD in gastric cancer
was four times higher than that of normal tissue. Besides,
LVD was significantly correlated with p-Akt, p-mTOR,
VEGF-C and VEGF-D (p < 0.05). Notably, LVD as well as
VEGF-C/-D was obviously lower in patients with negative
expression of p-Akt and p-mTOR than positive ones. It
suggested that both Akt/mTOR pathway and VEGF path-
way involved in lymphangiogenesis and lymphatic vessel
metastasis in gastric cancer. Similar results were also con-
firmed by other studies. Yu et al. suggested that p-mTOR
were highly consistent with lymph node metastasis and
could be an independent predictor of lymphatic metastasis
and prognosis of gastric cancer [22]. Besides, Onogawa
et al. indicated that VEGF-C was highly correlated with
lymphatic metastasis according to a study conducted in
140 cases of early gastric cancer [23]. VEGF-C as well asVEGF-D was also regarded as a predictor of lymphatic
metastasis in patients with early gastric cancer [24]. In the
study, we further confirmed the relationship of Akt/
mTOR, VEGF-C/-D and LVD in gastric cancer in situ.
LY294002, as an Akt activation inhibitor, is confirmed
with the anti-tumor effect and promoted the apoptosis
of gastric cancer in vitro and in vivo [25]. Rapamycin
known as an mTOR activation inhibitor is clinically used
for its anti-tumor effect and immunomodulation [26].
The results of our study further verified that LY294002
and Rapamycin could efficiently inhibit the growth
of SGC-7901 cells. Besides, LY294002 at 50 μM) and
Rapamycin at 100 nM had the most effective inhib-
ition rate of (52.53 ± 3.19) % and (48.72 ± 3.06) % at
24 h. When prolonging to 72 h, the inhibition rates
were (68.76 ± 1.00) % and (68.50 ± 3.77) % respectively.
Then, we observed the influence of phosphorylation in-
hibition of Akt and mTOR on lymphatic factors, VEGF-C
and VEGF-D. High concentration of LY294002 (50 μM)
and Rapamycin (100 nM) were used for the intervention
study. According to the results, Rapamycin suppressed the
expression of p-mTOR and LY294002 efficiently inhibited
the expression of p-Akt as well as p-mTOR. It is noted
that both inhibitors could efficiently inhibit the ex-
pression of VEGF-C/-D. Besides, the down-regulation of
p-Akt/p-mTOR showed a high consistency with that of
VEGF-C/-D. Therefore, Akt/mTOR pathway was pro-
posed to be closely related to VEGF-C/-D. The similar
results were also previously reported in other tumor
models. For example, Zhang et al. decreased the insulin
receptor by short hairpin RNA in cancer cell lines, LCC6
and T47D. The cell proliferation, angiogenesis, lym-
phangiogenesis and metastasis were also inhibited due
to the down-regulation of p-Akt and inactivation of
VEGF-D [27]. Besides, mTOR inhibition could suppress
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phangiogenesis in pancreatic cancer mouse model [11].
In another study, VEGF-D was degraded by Honokiol to
inhibit lymphangiogenesis of lung cancer xenograft [28].
IL-6 could also regulate VEGF-C at mRNA level through
Akt/mTOR signaling pathway, which effectively decreased
the lymphangiogenesis and metastasis in oral squamous
cell carcinoma [29].
Conclusion
The level of LVD in gastric cancer specimens was signifi-
cant higher than that of normal gastric tissue and posi-
tively correlated with immunohistochemistry staining of
p-Akt, p-mTOR, VEGF-C and VEGF-D. With the inhib-
ition of p-Akt and p-mTOR in vitro, VEGF-C and
VEGF-D were also significantly decreased. Therefore, we
propose that lymphangiogenesis of gastric cancer might
be efficiently modulated through Akt/mTOR-VEGF-C/
VEGF-D axis.
Abbreviation
LVD: Lymphatic vessel density.
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